Related Experiment Video
Updated: Jun 20, 2026

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
Human umbilical cord blood stem cells, myocardial infarction and stroke
Nathan Copeland1, David Harris, Mohamed A Gaballa
1University of Arizona Medical School, Tucson, Arizona, USA.
Insights
Human umbilical cord blood (hUCB) stem cells show promise for treating heart disease and stroke. This review highlights their beneficial effects in preclinical trials, offering a potential new cell therapy strategy.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Stem Cell Biology
Background:
- Myocardial infarction (MI) and stroke are leading causes of death in the USA.
- Despite advances, heart disease diagnoses are increasing, necessitating novel therapeutic strategies.
- Cell-based therapy is a promising area for treating cardiovascular diseases, with ongoing clinical trials.
Purpose of the Study:
- To critically review the beneficial effects of human umbilical cord blood (hUCB) cell therapy.
- To evaluate hUCB as a potential cell source for treating MI and stroke.
- To assess the suitability of hUCB-derived stem cells in preclinical settings.
Main Methods:
- Literature review of preclinical studies on hUCB cell therapy.
- Analysis of stem cell sources for cardiovascular regenerative medicine.
- Evaluation of hUCB cell characteristics, including multipotency and immunogenicity.
Main Results:
- hUCB is readily available and presents minimal ethical concerns.
- Stem cells derived from hUCB are multipotent and immunologically naive.
- Preclinical data suggest beneficial effects of hUCB cell therapy in cardiovascular disease models.
Conclusions:
- hUCB represents a logical and advantageous source for stem cells in cell-based therapies.
- hUCB cell therapy shows potential for treating myocardial infarction and stroke.
- Further investigation into hUCB cell therapy is warranted for clinical application.
Abstract:
Myocardial infarction (MI) and stroke are the first and third leading causes of death in the U.S.A. accounting for more than 1 in 3 deaths per annum. Despite interventional and pharmaceutical advances, the number of people diagnosed with heart disease is on the rise. Therefore, new clinical strategies are needed. Cell-based therapy holds great promise for treatment of these diseases and is currently under extensive preclinical as well as clinical trials. The source and types of stem cells for these clinical applications are questions of great interest. Human umbilical cord blood (hUCB) appears to be a logical candidate as a source of cells. hUCB is readily available, and presents little ethical challenges. Stem cells derived from hUCB are multipotent and immunologically naive. Here is a critical literature review of the beneficial effects of hUCB cell therapy in preclinical trials.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Stem Cell Culture
iPS Cell Differentiation
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

